ArticlePloS one2025
The DR score in RETeval™ electroretinogram system facilitates expeditious and uncomplicated early detection and assessment of diabetic polyneuropathy in clinical practice.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe principal aim of this investigation was to assess the utility of a novel DR score for the early detection of diabetic polyneuropathy (DPN). This score, currently integrated into the RETeval™ electroretinogram (ERG) system, is derived from parameters such as ERG wave characteristics, patient age, and pupillary response. Traditional nerve conduction studies (NCS), though valuable, have notable limitations, including the necessity for costly equipment and specialized personnel. Consequently, it was postulated that the DR score-initially devised for predicting diabetic retinopathy-might serve as a practical alternative for diagnosing DPN. This study sought to test the hypothesis that the DR score could offer a reliable means of both diagnosing DPN and estimating its severity.
methodsThe study retrospectively analyzed 82 diabetic patients admitted to Aichi Medical University Hospital between November 2016 and January 2019. ERG was performed using the RETeval™ device, and NCS was conducted to classify DPN stages according to the Baba's Differentiation Classification (BDC) system. Multiple regression analysis and receiver operating characteristics (ROC) analysis were employed to assess the relationship between the DR score and DPN stages.
resultsAmong 82 participants, 24.4% (n = 20) had no DPN (stage 0), and 75.6% (n = 62) had stage 1 or higher DPN. The DR score was significantly correlated with various clinical parameters, including nerve conduction velocities and the severity of DPN as classified by BDC stages. The regression model showed that both the DR score and age were significant predictors of DPN severity. The ROC analysis demonstrated that the DR score had a moderate ability to discriminate between no DPN and stage 1 or more of DPN, with an area under the ROC curve of 0.738.
conclusionsIn conclusion, this study involving 82 patients suggests that the DR score may be a valuable tool for the early detection and staging of DPN, potentially offering a more accessible and cost-effective alternative to traditional NCS, with significant implications for improving diabetic care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.